Proteomics Separates Adult-type Diffuse High-grade Gliomas in Metabolic Subgroups Independent of 1p/19q Codeletion and Across IDH Mutational Status

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2022 Dec 30

PMID 36584682

Authors

Jakob Maximilian Bader

Nikolaus Deigendesch

Martin Misch

Matthias Mann

Arend Koch

Felix Meissner

Affiliations

Soon will be listed here.

Abstract

High-grade adult-type diffuse gliomas are malignant neuroepithelial tumors with poor survival rates in combined chemoradiotherapy. The current WHO classification is based on IDH1/2 mutational and 1p/19q codeletion status. Glioma proteome alterations remain undercharacterized despite their promise for a better molecular patient stratification and therapeutic target identification. Here, we use mass spectrometry to characterize 42 formalin-fixed, paraffin-embedded (FFPE) samples from IDH-wild-type (IDHwt) gliomas, IDH-mutant (IDHmut) gliomas with and without 1p/19q codeletion, and non-neoplastic controls. Based on more than 5,500 quantified proteins and 5,000 phosphosites, gliomas separate by IDH1/2 mutational status but not by 1p/19q status. Instead, IDHmut gliomas split into two proteomic subtypes with widespread perturbations, including aerobic/anaerobic energy metabolism. Validations with three independent glioma proteome datasets confirm these subgroups and link the IDHmut subtypes to the established proneural and classic/mesenchymal subtypes in IDHwt glioma. This demonstrates common phenotypic subtypes across the IDH status with potential therapeutic implications for patients with IDHmut gliomas.

Citing Articles

Overlap of Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Matched Tissues for Proteomics and Phosphoproteomics.

Humphries E, Hains P, Robinson P ACS Omega. 2025; 10(7):6891-6900.

PMID: 40028131 PMC: 11865994. DOI: 10.1021/acsomega.4c09289.

Tumour-wide RNA splicing aberrations generate actionable public neoantigens.

Kwok D, Stevers N, Etxeberria I, Nejo T, Colton Cove M, Chen L Nature. 2025; 639(8054):463-473.

PMID: 39972144 PMC: 11903331. DOI: 10.1038/s41586-024-08552-0.

Proteomic profiling of gliomas unveils immune and metabolism-driven subtypes with implications for anti-nucleotide metabolism therapy.

Zhang J, Sun R, Lyu Y, Liu C, Liu Y, Feng Y Nat Commun. 2024; 15(1):10005.

PMID: 39562821 PMC: 11577044. DOI: 10.1038/s41467-024-54352-5.

Contrast-enhanced ultrasound can differentiate the level of glioma infiltration and correlate it with biological behavior: a study based on local pathology.

Hu X, Zhang G, Xie R, Wang Y, Zhu Y, Ding H J Ultrasound. 2024; .

PMID: 39489864 DOI: 10.1007/s40477-024-00961-1.

MSFragger-DDA+ Enhances Peptide Identification Sensitivity with Full Isolation Window Search.

Yu F, Deng Y, Nesvizhskii A bioRxiv. 2024; .

PMID: 39463976 PMC: 11507693. DOI: 10.1101/2024.10.12.618041.

References

Maurya P, Mishra A, Yadav B, Singh S, Kumar P, Chaudhary A . Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target. J Cancer. 2017; 8(10):1900-1907. PMC: 5556654. DOI: 10.7150/jca.17689. View

Feng T, Liu Y, Li C, Li Z, Cai H . DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis. Tumour Biol. 2017; 39(7):1010428317716248. DOI: 10.1177/1010428317716248. View

Chen R, Zhu J, Dong Y, He C, Hu X . Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells. Oncotarget. 2015; 6(32):32841-55. PMC: 4741733. DOI: 10.18632/oncotarget.5301. View

Govaere O, Petz M, Wouters J, Vandewynckel Y, Scott E, Topal B . The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene. 2017; 36(47):6605-6616. PMC: 5702717. DOI: 10.1038/onc.2017.260. View

Stone A, Bobo W, Brat D, Devi N, Van Meir E, Vertino P . Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol. 2004; 165(4):1151-61. PMC: 1618625. DOI: 10.1016/S0002-9440(10)63376-7. View

Sharma K, Schmitt S, Bergner C, Tyanova S, Kannaiyan N, Manrique-Hoyos N . Cell type- and brain region-resolved mouse brain proteome. Nat Neurosci. 2015; 18(12):1819-31. PMC: 7116867. DOI: 10.1038/nn.4160. View

Fu H, Ge B, Chen D, Wu Y, Luo Q, Li X . Phytanoyl-CoA 2-Hydroxylase-Interacting Protein-Like Gene Is a Therapeutic Target Gene for Glioblastoma Multiforme. Med Sci Monit. 2019; 25:2583-2590. PMC: 6474294. DOI: 10.12659/MSM.913895. View

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister S . ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013; 126(3):443-51. DOI: 10.1007/s00401-013-1156-z. View

Baskin R, Woods N, Mendoza-Fandino G, Forsyth P, Egan K, Monteiro A . Functional analysis of the 11q23.3 glioma susceptibility locus implicates PHLDB1 and DDX6 in glioma susceptibility. Sci Rep. 2015; 5:17367. PMC: 4661592. DOI: 10.1038/srep17367. View

10.

Yamini B . NF-κB, Mesenchymal Differentiation and Glioblastoma. Cells. 2018; 7(9). PMC: 6162779. DOI: 10.3390/cells7090125. View

11.

Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung W . MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Mol Cancer Ther. 2016; 15(7):1656-68. PMC: 4936927. DOI: 10.1158/1535-7163.MCT-15-0857. View

12.

Korber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z . Evolutionary Trajectories of IDH Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell. 2019; 35(4):692-704.e12. DOI: 10.1016/j.ccell.2019.02.007. View

13.

Lee H, Bartsch D, Xiao C, Guerrero S, Ahuja G, Schindler C . A post-transcriptional program coordinated by CSDE1 prevents intrinsic neural differentiation of human embryonic stem cells. Nat Commun. 2017; 8(1):1456. PMC: 5682285. DOI: 10.1038/s41467-017-01744-5. View

14.

Han M, Xu R, Xu Y, Zhang X, Ni S, Huang B . TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas. J Exp Clin Cancer Res. 2017; 36(1):155. PMC: 5674233. DOI: 10.1186/s13046-017-0619-9. View

15.

Gupta M, Polisetty R, Sharma R, Ganesh R, Gowda H, Purohit A . Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion. Sci Rep. 2019; 9(1):10986. PMC: 6662741. DOI: 10.1038/s41598-019-47360-9. View

16.

Bignone P, Lee K, Liu Y, Emilion G, Finch J, Soosay A . RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene. 2006; 26(5):683-700. DOI: 10.1038/sj.onc.1209827. View

17.

Mazurek M, Litak J, Kamieniak P, Kulesza B, Jonak K, Baj J . Metformin as Potential Therapy for High-Grade Glioma. Cancers (Basel). 2020; 12(1). PMC: 7016983. DOI: 10.3390/cancers12010210. View

18.

Chen J, McKay R, Parada L . Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012; 149(1):36-47. PMC: 3719882. DOI: 10.1016/j.cell.2012.03.009. View

19.

Wang R, Gurguis C, Gu W, Ko E, Lim I, Bang H . Ion channel gene expression predicts survival in glioma patients. Sci Rep. 2015; 5:11593. PMC: 4522676. DOI: 10.1038/srep11593. View

20.

Garofano L, Migliozzi S, Oh Y, DAngelo F, Najac R, Ko A . Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021; 2(2):141-156. PMC: 7935068. DOI: 10.1038/s43018-020-00159-4. View